About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Drugmaker Shire Agrees to $54-Billion Takeover from AbbVie

by Bidita Debnath on July 20, 2014 at 11:19 PM
Font : A-A+

 Drugmaker Shire Agrees to $54-Billion Takeover from AbbVie

In a deal aimed at slashing the US giant's tax bill, Shire Pharmaceuticals has accepted a £32-billion ($54-billion, 40-billion-euro) takeover bid from AbbVie, the two companies announced on Friday.

The takeover, priced with a 53.0-percent premium for Shire stock, comes after Shire, based in Ireland, reversed its opposition to a deal earlier this week.

Advertisement

"The boards of AbbVie and Shire are pleased to announce that they have reached agreement on the terms of a recommended combination of Shire with AbbVie," the two firms said in a statement.

The offer, comprising £24.44 in cash and 0.8960 AbbVie share per Shire share, is the same as the proposal received by the group last Sunday.

The companies added that the bid was worth the equivalent of £53.19 per Shire share, which represents a premium of 53 percent to the closing share price on May 2, one day before AbbVie's initial proposal.
Advertisement

The deal was expected to reduce AbbVie's effective tax rate to about 13 percent by 2016, according to the statement.

In late morning London deals, Shire's share price jumped 2.21 percent to £49.12 on the capital's FTSE 100 index, which was down 0.61 percent.

AbbVie stressed that it will "maintain a strong commitment" to growing the shareholder dividend and implementing a "significant" share repurchase scheme.

Shire Pharmaceuticals, which is listed in London and New York but based in Dublin, is a specialist in drugs for the treatment of attention-deficit disorder and rare diseases.

"The transaction will create a well-positioned and focused specialty biopharmaceutical company, with sustainable leadership positions within areas of unmet need, including immunology, rare diseases, neuroscience, metabolic diseases and liver disease and multiple emerging oncology programs," the statement added.

Shire shareholders will own approximately 25 percent of the combined company following completion of the takeover.

Shire, which provides treatments in areas such as rare diseases and neuroscience and is developing products in other therapeutic areas, had previously rejected offers from AbbVie as undervaluing the company.

The group had also previously highlighted concerns over AbbVie's plans to make Britain its home base for tax purposes.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
First-Ever Successful Pig-To-Human Kidney Transplantation
World Osteoporosis Day 2021 -
Spirituality and Mental Health
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
Stricter Pharmaceutical Patents Could Reduce Access to Affordable Drugs for the Poor
The American government's plans to adopt stricter pharmaceutical patents at the ongoing talks on a ....
Resistance to Certain Anticancer Drugs? New Nanopharmaceutical may Come In Handy
A clinical trial found that nanopharmaceutical drug CRLX101 is showing promise as a potential new .....
Japanese Pharmaceutical Company Starts Down's Therapy Test
A pharmaceutical company in Japan said it will begin therapeutic testing of a drug it hopes will ......
Pharmaceutical Companies Delay Drug Access, Not Processing Time
The pharmaceutical company submissions to Health Canada is delaying the access to new prescription ....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use